Active Ingredient History
Oprelvekin is recombinant interleukin eleven (IL-11), a thrombopoietic growth factor that directly stimulates the proliferation of hematopoietic stem cells and megakaryocyte progenitor cells and induces megakaryocyte maturation resulting in increased platelet production. It is marketed under the trade name Neumega. Wikipedia
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Breast Neoplasms (Phase 2)
Colitis, Ulcerative (Phase 1)
Colorectal Neoplasms (Phase 2)
Crohn Disease (Phase 2)
Gestational Trophoblastic Disease (Phase 2)
Hematologic Diseases (Phase 2/Phase 3)
Hemophilia A (Phase 2)
Inflammatory Bowel Diseases (Phase 2)
Kidney Neoplasms (Phase 2)
Leukemia (Phase 2)
Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)
Lymphoma (Phase 2)
Lymphoma, B-Cell, Marginal Zone (Phase 2)
Lymphoma, Follicular (Phase 2)
Nasopharyngeal Carcinoma (Phase 3)
Neoplasms (Phase 1)
Neuroblastoma (Phase 2)
Ovarian Neoplasms (Phase 2)
Sarcoma (Phase 2)
Testicular Neoplasms (Phase 2)
Thrombocytopenia (Phase 2/Phase 3)
von Willebrand Diseases (Phase 2)
Waldenstrom Macroglobulinemia (Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
